Bristol-Myers Squibb Co.

NYSE:BMY   11:11:35 AM EDT
64.15
+0.29 (+0.45%)
Products

Bristol-Myers Squibb Says FDA Accepts For Priority Review Supplemental BLA For Reblozyl

Published: 12/03/2021 12:09 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Accepts for Priority Review Supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults With Non-transfusion Dependent (ntd) Beta Thalassemia.
Bristol-myers Squibb Co - FDA Has Set a Prescription Drug User Fee Act (pdufa) Goal Date of March 27, 2022.